Ivan Babic
Overview
Explore the profile of Ivan Babic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1232
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mukherjee A, Waters A, Babic I, Nurmemmedov E, Glassy M, Kesari S, et al.
Hum Antibodies
. 2018 Sep;
27(1):53-62.
PMID: 30223393
Antibody drug conjugates (ADCs) represent a promising and an efficient strategy for targeted cancer therapy. Comprised of a monoclonal antibody, a cytotoxic drug, and a linker, ADCs offer tumor selectively,...
12.
Babic I, Kesari S, Nurmemmedov E
Future Med Chem
. 2018 Jun;
10(14):1641-1644.
PMID: 29957028
No abstract available.
13.
Babic I, Yenugonda V, Kesari S, Nurmemmedov E
Future Med Chem
. 2018 May;
10(12):1399-1403.
PMID: 29779411
No abstract available.
14.
Yenugonda V, Nomura N, Kouznetsova V, Tsigelny I, Fogal V, Nurmemmedov E, et al.
J Transl Med
. 2017 Oct;
15(1):210.
PMID: 29047383
Background: The mitochondrial protein p32 is a validated therapeutic target of cancer overexpressed in glioma. Therapeutic targeting of p32 with monoclonal antibody or p32-binding LyP-1 tumor-homing peptide can limit tumor...
15.
Babic I, Nurmemmedov E, Yenugonda V, Juarez T, Nomura N, Pingle S, et al.
Hum Antibodies
. 2017 Oct;
26(2):95-101.
PMID: 29036806
Immunotherapy is now at the forefront of cancer therapeutic development. Gliomas are a particularly aggressive form of brain cancer for which immunotherapy may hold promise. Pritumumab (also known in the...
16.
Tao Z, Li S, Ichim T, Yang J, Riordan N, Yenugonda V, et al.
Immunotherapy
. 2017 Jun;
9(7):589-606.
PMID: 28595516
The clinical success of checkpoint inhibitors has led to a renaissance of interest in cancer immunotherapies. In particular, the possibility of ex vivo expanding autologous lymphocytes that specifically recognize tumor...
17.
Tsigelny I, Mukthavaram R, Kouznetsova V, Chao Y, Babic I, Nurmemmedov E, et al.
Oncotarget
. 2015 Oct;
8(14):22370-22384.
PMID: 26517684
Transcription factors (TFs) are a major class of protein signaling molecules that play key cellular roles in cancers such as the highly lethal brain cancer-glioblastoma (GBM). However, the development of...
18.
Fogal V, Babic I, Chao Y, Pastorino S, Mukthavaram R, Jiang P, et al.
Oncotarget
. 2014 Dec;
6(2):1157-70.
PMID: 25528767
Metabolic reprogramming is a key feature of tumorigenesis that is controlled by oncogenes. Enhanced utilization of glucose and glutamine are the best-established hallmarks of tumor metabolism. The oncogene c-Myc is...
19.
Banovic M, Mahovlic V, Meljanac Salopek K, Banovic V, Babic I, Oreskovic S, et al.
Pathol Oncol Res
. 2014 Nov;
21(3):613-7.
PMID: 25432549
No abstract available.
20.
Banovic V, Skrablin S, Banovic M, Rados M, Gveric-Ahmetasevic S, Babic I
Int J Gynaecol Obstet
. 2014 Apr;
125(3):237-40.
PMID: 24680842
Objective: To determine the incidence of fetal brain injury by fetal brain magnetic resonance imaging (MRI) in pregnancies complicated with preterm labor (PL), preterm premature rupture of the membranes (PPROM),...